Literature DB >> 31087124

Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up.

Anne M Horne1, Borislav Mihov1, Ian R Reid2,3.   

Abstract

Entities:  

Year:  2019        PMID： 31087124     DOI： 10.1007/s00223-019-00553-w

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


× No keyword cloud information.
  5 in total

Review 1.  Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.

Authors:  Pojchong Chotiyarnwong; Eugene V McCloskey
Journal:  Nat Rev Endocrinol       Date:  2020-04-14       Impact factor: 43.330

Review 2.  UK clinical guideline for the prevention and treatment of osteoporosis.

Authors:  Celia L Gregson; David J Armstrong; Jean Bowden; Cyrus Cooper; John Edwards; Neil J L Gittoes; Nicholas Harvey; John Kanis; Sarah Leyland; Rebecca Low; Eugene McCloskey; Katie Moss; Jane Parker; Zoe Paskins; Kenneth Poole; David M Reid; Mike Stone; Julia Thomson; Nic Vine; Juliet Compston
Journal:  Arch Osteoporos       Date:  2022-04-05       Impact factor: 2.879

Review 3.  Should denosumab treatment for osteoporosis be continued indefinitely?

Authors:  Jane A Noble; Malachi J McKenna; Rachel K Crowley
Journal:  Ther Adv Endocrinol Metab       Date:  2021-04-22       Impact factor: 3.565

4.  Osteoporosis in 10 years time: a glimpse into the future of osteoporosis.

Authors:  Giovanni Adami; Angelo Fassio; Davide Gatti; Ombretta Viapiana; Camilla Benini; Maria I Danila; Kenneth G Saag; Maurizio Rossini
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-03-20       Impact factor: 5.346

5.  Bone Mineral Density After Transitioning From Denosumab to Alendronate.

Authors:  David Kendler; Arkadi Chines; Patricia Clark; Peter R Ebeling; Michael McClung; Yumie Rhee; Shuang Huang; Robert Kees Stad
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.